Alankrita Taneja

Alankrita Taneja

Auto-generated profile, based on publicly available information

Alankrita Taneja

Armed Forces Medical College, Pune, India

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2019 in European Journal of Haematology
Verified
Journal Article
Open access
PDF file
ATAlankrita Taneja
Alankrita Taneja
VKVivek Kumar
Vivek Kumar
ACAbhinav B. Chandra
Abhinav B. Chandra
Objective: Primary renal lymphoma (PRL) is defined as a non‐Hodgkin lymphoma (NHL) restricted to kidneys without extensive nodal disease. The literature on epidemiology and outcome in PRL is limited to case reports and small case series.Methods: We utilized Surveillance, Epidemiology, and End Result database (1984‐2015) to study the demographic, clinical, and pathological characteristics of PRL. We conducted analysis to assess factors associated with overall survival (OS) and cause‐specific survival (CSS).Results: A total of 599 (0.17% of all NHL) patients were eligible for the study. The age‐adjusted incidence was 0.035/100,000 population and is increasing. The median age was 72 years, and most of the patients were Caucasians and were males. Most of the patients had unilateral tumors, and diffuse large B‐cell lymphoma (DLBCL) was the most common histologic type. The median OS was 112 months, while median CSS was not reached. Age ≥ 60 years was the strongest independent risk factor for worse OS and CSS, while non‐DLBCL histology was associated with better OS and CSS.Discussion: Primary renal lymphoma is a rare lymphoma with increasing incidence in more recent years. In this study, we describe demographic, clinical, and pathological characteristics of PRL and factors affecting survival among these patients.

4 December 2019 in Journal of Medical Internet Research
Verified
Journal Article
Open access
LKLakshmanan Krishnamurti
Lakshmanan Krishnamurti
DRDiana Ross
Diana Ross
CSCynthia Sinha
Cynthia Sinha
TLTraci Leong
Traci Leong
NBNamita Bakshi
Namita Bakshi
GLGeorge Loewenstein
George Loewenstein
Background: Hydroxyurea, chronic blood transfusions, and bone marrow transplantation are efficacious, disease-modifying therapies for sickle cell disease but involve complex risk-benefit trade-offs and decisional dilemma compounded by the lack of comparative studies. A patient decision aid can inform patients about their treatment options, the associated risks and benefits, help them clarify their values, and allow them to participate in medical decision making. Objective: The objective of this study was to develop a literacy-sensitive Web-based patient decision aid based on the Ottawa decision support framework, and through a randomized clinical trial estimate the effectiveness of the patient decision aid in improving patient knowledge and their involvement in decision making. Methods: We conducted population decisional needs assessments in a nationwide sample of patients, caregivers, community advocates, policy makers, and health care providers using qualitative interviews to identify decisional conflict, knowledge and expectations, values, support and resources, decision types, timing, stages and learning, and personal clinical characteristics. Interview transcripts were coded using QSR NVivo 10. Alpha testing of the patient decision aid prototype was done to establish usability and the accuracy of the information it conveyed, and then was followed by iterative cycles of beta testing. We conducted a randomized clinical trial of adults and of caregivers of pediatric patients to evaluate the efficacy of the patient decision aid. Results: In a decisional needs assessment, 223 stakeholders described their preferences, helping to guide the development of the patient decision aid, which then underwent alpha testing by 30 patients and 38 health care providers and iterative cycles of beta testing by 87 stakeholders. In a randomized clinical trial, 120 participants were assigned to either the patient decision aid or standard care (SC) arm. Qualitative interviews revealed high levels of usability, acceptability, and utility of the patient decision aid in education, values clarification, and preparation for decision making. On the acceptability survey, 72% (86/120) of participants rated the patient decision aid as good or excellent. Participants on the patient decision aid arm compared to the SC arm demonstrated a statistically significant improvement in decisional self-efficacy (P=.05) and a reduction in the informed sub-score of decisional conflict (P=.003) at 3 months, with an improvement in preparation for decision making (P<.001) at 6 months. However, there was no improvement in terms of the change in knowledge, the total or other domain scores of decisional conflicts, or decisional self-efficacies at 6 months. The large amount of missing data from survey completion limited our ability to draw conclusions about the effectiveness of the patient decision aid. The patient decision aid met 61 of 62 benchmarks of the international patient decision aid collaboration standards for content, development process, and efficacy. Conclusions: We have developed a patient decision aid for sickle cell disease with extensive input from stakeholders and in a randomized clinical trial demonstrated its acceptability and utility in education and decision making. We were unable to demonstrate its effectiveness in improving patient knowledge and involvement in decision making. Trial Registration: ClinicalTrials.gov NCT03224429; https://clinicaltrials.gov/ct2/show/NCT03224429 and ClinicalTrials.gov NCT02326597; https://clinicaltrials.gov/ct2/show/NCT02326597

8 February 2018 in Science and Engineering Ethics
Verified
Journal Article
Closed access
PDF file
ATAlankrita Taneja
Alankrita Taneja
SDSiddhartha Das
Siddhartha Das
SHSyed Ather Hussain
Syed Ather Hussain
MMMohammed Madadin
Mohammed Madadin
SLStany Wilfred Lobo
Stany Wilfred Lobo
RMRitesh G Menezes
Ritesh G Menezes

4 May 2018 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
ASAyman Saad
Ayman Saad
ATAlankrita Taneja
Alankrita Taneja
ASAntonio Di Stasi
Antonio Di Stasi
RSRehan Sarmad
Rehan Sarmad
RKRivvi Kukkamalla
Rivvi Kukkamalla
SMShin Mineishi
Shin Mineishi

6 July 2018 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
ATAlankrita Taneja
Alankrita Taneja
JJJade Jones
Jade Jones
SPStefania Pittaluga
Stefania Pittaluga
IMIrina Maric
Irina Maric
MFMohammed Farooqui
Mohammed Farooqui
CSClare Sun
Clare Sun
(2018). Richter transformation to Hodgkin lymphoma on Bruton’s tyrosine kinase inhibitor therapy. Leukemia & Lymphoma. Ahead of Print.

28 December 2018 in Advances in Cell and Gene Therapy
Verified
Journal Article
Open access
PDF file
ATAlankrita Taneja
Alankrita Taneja
JCJoseph H. Chewning
Joseph H. Chewning
ASAyman Saad
Ayman Saad
Viral infections are common causes of morbidity and mortality in patients undergoing hematopoietic stem cell transplantation (HSCT). In particular, allogeneic HSCT induces a profound immunocompromised state that may last up to 24 months post transplant, or longer in case of chronic graft versus host disease (GVHD). The common viruses affecting HSCT patients are HSV, VZV, CMV, EBV, adenovirus, HHV6, BK virus and upper respiratory viruses such as influenza, parainfluenza, and RSV. These infections typically occur in three distinct phases: pre‐engraftment, early post‐engraftment, and late post‐engraftment. This review will have two major sections, the first will discuss the epidemiology and natural history of different viral infections and second part will discuss preventive and therapeutic strategies among HSCT patients.